Divi's Laboratories Limited (NSE:DIVISLAB)
India
· Delayed Price · Currency is INR 5,757.05
-221.25 (-3.70%)
Feb 21, 2025, 3:29 PM IST
Divi's Laboratories Employees
Divi's Laboratories had 9,741 employees as of March 31, 2024. The number of employees increased by 1,308 or 15.51% compared to the previous year.
Employees
9,741
Change (1Y)
1,308
Growth (1Y)
15.51%
Revenue / Employee
9.32M INR
Profits / Employee
2.12M INR
Market Cap
1,528.32B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 9,741 | 1,308 | 15.51% |
| Mar 31, 2023 | 8,433 | -8,110 | -49.02% |
| Mar 31, 2022 | 16,543 | -275 | -1.64% |
| Mar 31, 2021 | 16,818 | 2,934 | 21.13% |
| Mar 31, 2020 | 13,884 | 2,037 | 17.19% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sun Pharmaceutical Industries | 43,000 |
| Cipla | 27,764 |
| Mankind Pharma | 19,540 |
| Apollo Hospitals Enterprise | 83,147 |
| Zydus Lifesciences | 26,921 |
| Aurobindo Pharma | 26,015 |
| Alkem Laboratories | 17,432 |
| Fortis Healthcare | 12,088 |
Divi's Laboratories News
- 13 days ago - Divi's Laboratories Ltd (BOM:532488) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... - GuruFocus
- 13 days ago - Q3 2025 Divi's Laboratories Ltd Earnings Call Transcript - GuruFocus
- 18 days ago - Divi’s Labs remains our top pick, target price at Rs 6,850 after Q3 results: Citi - Business Upturn
- 2 months ago - Citi reaffirms ‘Buy’ on Divi’s Laboratories, sees buying opportunities amid BioSecure delays - Business Upturn
- 3 months ago - Divi's Laboratories Ltd (BOM:532488) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst ... - GuruFocus
- 3 months ago - Q2 2025 Divi's Laboratories Ltd Earnings Call Transcript - GuruFocus
- 4 months ago - Divis Labs surges over 4.5% on positive brokerage report - Business Upturn
- 4 months ago - Citi initiates Buy on Divis Lab, sees 15% upside in share price - Business Upturn